ROS1-positive Lung Cancer Video Perspectives

In this video interview, Ravi Salgia, MD, PhD, the Arthur & Rosalie Kaplan Chair in Medical Oncology at City of Hope's comprehensive cancer center, discussed:

• the importance of biomarker testing of ROS1-positive lung cancer;
• the commonality of ROS1 mutations;
• populations affected by these mutations, such as younger patients and non-smoking patients;
• treatment options available to patients with ROS1-mutated lung cancer, such as entrectinib (Rozlytrek; Genentech) and crizotinib (Xalkori; Pfizer);
• what is in the pipeline for ROS1-mutated small cell lung cancer; and
• the challenges that exist in treatment and where future research should focus.